Related Experiment Video
Updated: Sep 9, 2025
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Asthma endotypes in flux: integrating type 1 and type 2 inflammation for biological therapy advancement
Picheswara Rao Polu1, Vamsi Krishna Bikki2
1Research and Development Cell, Department of Intellectual Property Rights, Lovely Professional University, Phagwara, Punjab, India.
Objective:
To synthesize current understanding of type 1 (T1) and type 2 (T2) asthma endotypes and evaluate how their integration can advance precision biological therapy selection for improved patient outcomes.
Data Sources:
Comprehensive literature review of peer-reviewed articles from PubMed, Embase, and Cochrane databases focusing on asthma immunopathology, endotype characterization, biomarker development, and biological therapies. Additional sources included clinical trial registries, regulatory agency documents, and recent conference proceedings.
Study Selection:
Studies were selected based on relevance to T1/T2 inflammatory pathways, biomarker validation, biological therapy efficacy, and endotype-guided treatment strategies. Priority was given to randomized controlled trials, systematic reviews, and large observational studies with clear endotype characterization.
Results:
T2 inflammation, characterized by interleukin-4 (IL-4), IL-5, and IL-13 pathways with eosinophilic involvement, has well-established biomarkers (blood eosinophils, fractional exhaled nitric oxide (FeNO), periostin) and successful targeted biologics (anti-IL-5, anti-IL-4 receptor alpha (anti-IL-4Rα), anti-immunoglobulin E (anti-IgE)). T1 inflammation, involving interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and IL-17 with neutrophilic predominance, lacks validated biomarkers and effective therapeutics. Emerging evidence demonstrates significant T1/T2 overlap in severe asthma, challenging traditional dichotomous classification. Multi-pathway targeting strategies and upstream cytokine inhibition show promise for mixed endotypes.
Conclusion:
Integration of T1 and T2 endotype characterization through validated biomarkers and multi-omics approaches is essential for advancing precision medicine in asthma. Future therapeutic strategies must address endotype plasticity and mixed inflammatory patterns to optimize biological therapy selection and improve treatment outcomes in heterogeneous asthma populations.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Asthma-I: Introduction
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: